Immunopathogenesis of paraneoplastic neurological syndromes associated with anti-Hu antibodies: A beneficial antitumor immune response going awry

OncoImmunology

Volumn 2, Issue 12, 2013, Pages

  Pignolet, Béatrice S L ^a,b,c,d   Gebauer, Christina M T ^a,b,c   Liblau, Roland S ^a,b,c,d  

^a INSER M UMR1043   (France)

^b CNRS   (France)

^c UNIVERSITÉ PAUL SABATIER   (France)

^d CHU PURPAN   (France)

Author keywords

Anti Hu syndrome; Autoimmunity; Cancer; Central nervous system; Paraneoplastic neurological disorder

Indexed keywords

HU ANTIBODY; HU PROTEIN;

ANTIGEN DETECTION; ANTIGEN EXPRESSION; AUTOIMMUNITY; CANCER CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DISEASE ASSOCIATION; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; NERVE CELL; PARANEOPLASTIC ENCEPHALOMYELOPATHY; PARANEOPLASTIC NEUROPATHY; PARANEOPLASTIC SENSORY NEURONOPATHY; REVIEW; TISSUE INJURY;

EID: 84896737598     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.27384     Document Type: Review

References (96)

1. Darnell RB, Posner JB. Observing the invisible: successful tumor immunity in humans. Nat Immunol 2003; 4:201; http://dx.doi.org/10.1038/ni0303-201; PMID:12605223
2. Seute T, Leffers P, ten Velde GP, Twijnstra A. Neurologic disorders in 432 consecutive patients with small cell lung carcinoma. Cancer 2004; 100:801-6; http://dx.doi.org/10.1002/cncr.20043; PMID:14770437
3. Graus F, Cordon-Cardo C, Posner JB. Neuronal antinuclear antibody in sensory neuronopathy from lung cancer. Neurology 1985; 35:538-43; PMID:2984600; http://dx.doi.org/10.1212/ WNL.35.4.538
4. Darnell RB, DeAngelis LM. Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies. Lancet 1993; 341:21-2; PMID:8093269; http://dx.doi. org/10.1016/0140-6736(93)92485-C
5. Honnorat J, Didelot A, Karantoni E, Ville D, Ducray F, Lambert L, Deiva K, Garcia M, Pichit P, Cavillon G, et al. Autoimmune limbic encephalopathy and anti-Hu antibodies in children without cancer. Neurology 2013; 80:2226-32; http:// dx.doi.org/10.1212/WNL.0b013e318296e9c3; PMID:23658383
6. Dalmau J, Graus F, Rosenblum MK, Posner JB. Anti-Hu--associated paraneoplastic encephalomyelitis/ sensory neuronopathy. A clinical study of 71 patients. Medicine (Baltimore) 1992; 71:59-72; PMID:1312211; http://dx.doi. org/10.1097/00005792-199203000-00001
7. Keime-Guibert F, Graus F, Broët P, Reñé R, Molinuevo JL, Ascaso C, Delattre JY. Clinical outcome of patients with anti-Hu-associated encephalomyelitis after treatment of the tumor. Neurology 1999; 53:1719-23; PMID:10563618; http://dx.doi. org/10.1212/WNL.53.8.1719
8. Monstad SE, Drivsholm L, Storstein A, Aarseth JH, Haugen M, Lang B, Vincent A, Vedeler CA. Hu and voltage-gated calcium channel (VGCC) antibodies related to the prognosis of small-cell lung cancer. J Clin Oncol 2004; 22:795-800; http://dx.doi. org/10.1200/JCO.2004.01.028; PMID:14990634
9. Graus F, Keime-Guibert F, Reñe R, Benyahia B, Ribalta T, Ascaso C, Escaramis G, Delattre JY. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 2001; 124:1138-48; PMID:11353730; http://dx.doi.org/10.1093/ brain/124.6.1138
10. Dalmau J, Furneaux HM, Gralla RJ, Kris MG, Posner JB. Detection of the anti-Hu antibody in the serum of patients with small cell lung cancer--a quantitative western blot analysis. Ann Neurol 1990; 27:544-52; http://dx.doi.org/10.1002/ana.410270515; PMID:2163235
11. Graus F, Dalmou J, Reñé R, Tora M, Malats N, Verschuuren JJ, Cardenal F, Viñolas N, Garcia del Muro J, Vadell C, et al. Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. J Clin Oncol 1997; 15:2866-72; PMID:9256130
12. Byrne KT, Turk MJ. New perspectives on the role of vitiligo in immune responses to melanoma. Oncotarget 2011; 2:684-94; PMID:21911918
13. Okano HJ, Darnell RB. A hierarchy of Hu RNA binding proteins in developing and adult neurons. J Neurosci 1997; 17:3024-37; PMID:9096138
14. Ma WJ, Cheng S, Campbell C, Wright A, Furneaux H. Cloning and characterization of HuR, a ubiquitously expressed Elav-like protein. J Biol Chem 1996; 271:8144-51; PMID:8626503; http://dx.doi. org/10.1074/jbc.271.14.8144
15. Robinow S, Campos AR, Yao KM, White K. The elav gene product of Drosophila, required in neurons, has three RNP consensus motifs. Science 1988; 242:1570-2; PMID:3144044; http://dx.doi. org/10.1126/science.3144044
16. Robinow S, White K. Characterization and spatial distribution of the ELAV protein during Drosophila melanogaster development. J Neurobiol 1991; 22:443-61; http://dx.doi.org/10.1002/ neu.480220503; PMID:1716300
17. Chung S, Jiang L, Cheng S, Furneaux H. Purification and properties of HuD, a neuronal RNA-binding protein. J Biol Chem 1996; 271:11518-24; PMID:8626712; http://dx.doi.org/10.1074/ jbc.271.19.11518
18. Bolognani F, Perrone-Bizzozero NI. RNA-protein interactions and control of mRNA stability in neurons. J Neurosci Res 2008; 86:481-9; http://dx.doi. org/10.1002/jnr.21473; PMID:17853436
19. Perrone-Bizzozero N, Bolognani F. Role of HuD and other RNA-binding proteins in neural development and plasticity. J Neurosci Res 2002; 68:121-6; PMID:11948657; http://dx.doi.org/10.1002/ jnr.10175
20. Allen M, Bird C, Feng W, Liu G, Li W, Perrone-Bizzozero NI, Feng Y. HuD promotes BDNF expression in brain neurons via selective stabilization of the BDNF long 3'UTR mRNA. PLoS One 2013; 8:e55718; http://dx.doi.org/10.1371/journal. pone.0055718; PMID:23383270
21. Ince-Dunn G, Okano HJ, Jensen KB, Park WY, Zhong R, Ule J, Mele A, Fak JJ, Yang C, Zhang C, et al. Neuronal Elav-like (Hu) proteins regulate RNA splicing and abundance to control glutamate levels and neuronal excitability. Neuron 2012; 75:1067-80; http://dx.doi.org/10.1016/j.neuron.2012.07.009; PMID:22998874
22. Anderson KD, Merhege MA, Morin M, Bolognani F, Perrone-Bizzozero NI. Increased expression and localization of the RNA-binding protein HuD and GAP-43 mRNA to cytoplasmic granules in DRG neurons during nerve regeneration. Exp Neurol 2003; 183:100-8; PMID:12957493; http://dx.doi. org/10.1016/S0014-4886(03)00103-1
23. Kasashima K, Terashima K, Yamamoto K, Sakashita E, Sakamoto H. Cytoplasmic localization is required for the mammalian ELAV-like protein HuD to induce neuronal differentiation. Genes Cells 1999; 4:667-83; PMID:10620013; http://dx.doi. org/10.1046/j.1365-2443.1999.00292.x
24. Fujiwara T, Fukao A, Sasano Y, Matsuzaki H, Kikkawa U, Imataka H, Inoue K, Endo S, Sonenberg N, Thoma C, et al. Functional and direct interaction between the RNA binding protein HuD and active Akt1. Nucleic Acids Res 2012; 40:1944-53; http:// dx.doi.org/10.1093/nar/gkr979; PMID:22075994
25. Manley GT, Smitt PS, Dalmau J, Posner JB. Hu antigens: reactivity with Hu antibodies, tumor expression, and major immunogenic sites. Ann Neurol 1995; 38:102-10; http://dx.doi.org/10.1002/ ana.410380117; PMID:7541976
26. Cho JH, Noguchi M. Expression of HuD (a paraneoplastic encephalomyelitis antigen) mRNA in lung cancer. J Korean Med Sci 1997; 12:305-10; PMID:9288629
27. Carpentier AF, Voltz R, DesChamps T, Posner JB, Dalmau J, Rosenfeld MR. Absence of HuD gene mutations in paraneoplastic small cell lung cancer tissue. Neurology 1998; 50:1919; PMID:9633765; http://dx.doi.org/10.1212/WNL.50.6.1919
28. D'Alessandro V, Muscarella LA, la Torre A, Bisceglia M, Parrella P, Scaramuzzi G, Storlazzi CT, Trombetta D, Kok K, De Cata A, et al. Molecular analysis of the HuD gene in neuroendocrine lung cancers. Lung Cancer 2010; 67:69-75; http://dx.doi.org/10.1016/j. lungcan.2009.03.022; PMID:19410329
29. Sekido Y, Bader SA, Carbone DP, Johnson BE, Minna JD. Molecular analysis of the HuD gene encoding a paraneoplastic encephalomyelitis antigen in human lung cancer cell lines. Cancer Res 1994; 54:4988-92; PMID:8069866
30. Gazdar AF, Carney DN, Becker KL, Deftos LJ, Liang V, Go W, Marangos PJ, Moody TW, Wolfsen AR, Zweig MH. Expression of peptide and other markers in lung cancer cell lines. Recent Results Cancer Res 1985; 99:167-74; PMID:2999915; http://dx.doi. org/10.1007/978-3-642-82533-0_17
31. Graus F, Elkon KB, Cordon-Cardo C, Posner JB. Sensory neuronopathy and small cell lung cancer. Antineuronal antibody that also reacts with the tumor. Am J Med 1986; 80:45-52; PMID:2417479; http://dx.doi.org/10.1016/0002-9343(86)90047-1
32. Vega F, Graus F, Chen QM, Poisson M, Schuller E, Delattre JY. Intrathecal synthesis of the anti-Hu antibody in patients with paraneoplastic encephalomyelitis or sensory neuronopathy: clinical-immunologic correlation. Neurology 1994; 44:2145-7; PMID:7969974; http://dx.doi. org/10.1212/WNL.44.11.2145
33. Verschuuren JJP, Perquin M, ten Velde G, De Baets M, Vriesman PB, Twijnstra A. Anti-Hu antibody titre and brain metastases before and after treatment for small cell lung cancer. J Neurol Neurosurg Psychiatry 1999; 67:353-7; PMID:10449558; http://dx.doi. org/10.1136/jnnp.67.3.353
34. Blaes F, Klotz M, Funke D, Strittmatter M, Kraus J, Kaps M. Disturbance in the serum IgG subclass distribution in patients with anti-Hu positive paraneoplastic neurological syndromes. Eur J Neurol 2002; 9:369-72; PMID:12099920; http://dx.doi. org/10.1046/j.1468-1331.2002.00416.x
35. Monstad SE, Knudsen A, Salvesen HB, Aarseth JH, Vedeler CA. Onconeural antibodies in sera from patients with various types of tumours. Cancer Immunol Immunother 2009; 58:1795-800; http://dx.doi.org/10.1007/s00262-009-0690-y; PMID:19294382
36. Greenlee JE, Boyden JW, Pingree M, Brashear HR, Clawson SA, Keeney PM. Antibody types and IgG subclasses in paraneoplastic neurological syndromes. J Neurol Sci 2001; 184:131-7; PMID:11239946; http://dx.doi.org/10.1016/S0022-510X(01)00442-7
37. Jean WC, Dalmau J, Ho A, Posner JB. Analysis of the IgG subclass distribution and inflammatory infiltrates in patients with anti-Hu-associated paraneoplastic encephalomyelitis. Neurology 1994; 44:140-7; PMID:8290049; http://dx.doi.org/10.1212/ WNL.44.1.140
38. Sodeyama N, Ishida K, Jaeckle KA, Zhang L, Azuma A, Yamada M, Mizusawa H, Wada Y. Pattern of epitopic reactivity of the anti-Hu antibody on HuD with and without paraneoplastic syndrome. J Neurol Neurosurg Psychiatry 1999; 66:97-9; PMID:9886463; http://dx.doi.org/10.1136/ jnnp.66.1.97
39. Furneaux HF, Reich L, Posner JB. Autoantibody synthesis in the central nervous system of patients with paraneoplastic syndromes. Neurology 1990; 40:1085-91; PMID:2356009; http://dx.doi. org/10.1212/WNL.40.7.1085
40. Graus F, Vega F, Delattre JY, Bonaventura I, Reñé R, Arbaiza D, Tolosa E. Plasmapheresis and antineoplastic treatment in CNS paraneoplastic syndromes with antineuronal autoantibodies. Neurology 1992; 42:536-40; PMID:1312683; http://dx.doi. org/10.1212/WNL.42.3.536
41. Rauer S, Kaiser R. Demonstration of anti-HuD specific oligoclonal bands in the cerebrospinal fluid from patients with paraneoplastic neurological syndromes. Qualitative evidence of anti-HuD specific IgG-synthesis in the central nervous system. J Neuroimmunol 2000; 111:241-4; PMID:11063845; http://dx.doi.org/10.1016/S0165-5728(00)00391-X
42. Dalmau J, Graus F, Cheung NK, Rosenblum MK, Ho A, Cañete A, Delattre JY, Thompson SJ, Posner JB. Major histocompatibility proteins, anti-Hu antibodies, and paraneoplastic encephalomyelitis in neuroblastoma and small cell lung cancer. Cancer 1995; 75:99-109; PMID:7804984; http://dx.doi. org/10.1002/1097-0142(19950101)75:1<99::AIDCNCR2820750117> 3.0.CO;2-I
43. Pittock SJ, Kryzer TJ, Lennon VA. Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol 2004; 56:715-9; http:// dx.doi.org/10.1002/ana.20269; PMID:15468074
44. Sillevis Smitt P, Grefkens J, de Leeuw B, van den Bent M, van Putten W, Hooijkaas H, Vecht C. Survival and outcome in 73 anti-Hu positive patients with paraneoplastic encephalomyelitis/sensory neuronopathy. J Neurol 2002; 249:745-53; http://dx.doi. org/10.1007/s00415-002-0706-4; PMID:12111309
45. Torà M, Graus F, de Bolòs C, Real FX. Cell surface expression of paraneoplastic encephalomyelitis/sensory neuronopathy-associated Hu antigens in smallcell lung cancers and neuroblastomas. Neurology 1997; 48:735-41; PMID:9065557; http://dx.doi. org/10.1212/WNL.48.3.735
46. De Giorgio R, Bovara M, Barbara G, Canossa M, Sarnelli G, De Ponti F, Stanghellini V, Tonini M, Cappello S, Pagnotta E, et al. Anti-HuD-induced neuronal apoptosis underlying paraneoplastic gut dysmotility. Gastroenterology 2003; 125:70-9; PMID:12851872; http://dx.doi.org/10.1016/ S0016-5085(03)00664-4
47. Greenlee JE, Parks TN, Jaeckle KA. Type IIa ('anti-Hu') antineuronal antibodies produce destruction of rat cerebellar granule neurons in vitro. Neurology 1993; 43:2049-54; PMID:8413965; http://dx.doi. org/10.1212/WNL.43.10.2049
48. Schäfer KH, Klotz M, Mergner D, Mestres P, Schimrigk K, Blaes F. IgG-mediated cytotoxicity to myenteric plexus cultures in patients with paraneoplastic neurological syndromes. J Autoimmun 2000; 15:479-84; http://dx.doi.org/10.1006/ jaut.2000.0454; PMID:11090247
49. Hormigo A, Lieberman F. Nuclear localization of anti-Hu antibody is not associated with in vitro cytotoxicity. J Neuroimmunol 1994; 55:205-12; PMID:7829670; http://dx.doi. org/10.1016/0165-5728(94)90011-6
50. Tanaka K, Ding X, Tanaka M. Effects of antineuronal antibodies from patients with paraneoplastic neurological syndrome on primary-cultured neurons. J Neurol Sci 2004; 217:25-30; PMID:14675605; http://dx.doi.org/10.1016/j.jns.2003.08.006
51. Sillevis Smitt PA, Manley GT, Posner JB. Immunization with the paraneoplastic encephalomyelitis antigen HuD does not cause neurologic disease in mice. Neurology 1995; 45:1873-8; PMID:7477985; http://dx.doi.org/10.1212/WNL.45.10.1873
52. Uchuya M, Graus F, Vega F, Reñé R, Delattre JY. Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with antineuronal autoantibodies. J Neurol Neurosurg Psychiatry 1996; 60:388-92; PMID:8774401; http://dx.doi. org/10.1136/jnnp.60.4.388
53. Sakai K, Gofuku M, Kitagawa Y, Ogasawara T, Hirose G. Induction of anti-Purkinje cell antibodies in vivo by immunizing with a recombinant 52-kDa paraneoplastic cerebellar degeneration-associated protein. J Neuroimmunol 1995; 60:135-41; PMID:7642741; http://dx.doi.org/10.1016/0165-5728(95)00063-8
54. Benyahia B, Liblau R, Merle-Béral H, Tourani JM, Dalmau J, Delattre JY. Cell-mediated autoimmunity in paraneoplastic neurological syndromes with anti-Hu antibodies. Ann Neurol 1999; 45:162-7; PMID:9989617; http://dx.doi.org/10.1002/1531-8249(199902)45:2<162::AID-ANA5>3.0.CO;2-R
55. de Beukelaar JW, Sillevis Smitt PA, Hop WC, Kraan J, Hooijkaas H, Verjans GM, Gratama JW. Imbalances in circulating lymphocyte subsets in Hu antibody associated paraneoplastic neurological syndromes. Eur J Neurol 2007; 14:1383-91; http:// dx.doi.org/10.1111/j.1468-1331.2007.01986.x; PMID:18028190
56. Tani T, Tanaka K, Idezuka J, Nishizawa M. Regulatory T cells in paraneoplastic neurological syndromes. J Neuroimmunol 2008; 196:166-9; http://dx.doi.org/10.1016/j.jneuroim.2008.03.002; PMID:18455243
57. Psimaras D, Carpentier AF, Rossi C; PNS Euronetwork. Cerebrospinal fluid study in paraneoplastic syndromes. J Neurol Neurosurg Psychiatry 2010; 81:42-5; http://dx.doi.org/10.1136/ jnnp.2008.159483; PMID:19324868
58. de Jongste AH, de Graaf MT, van den Broek PD, Kraan J, Smitt PA, Gratama JW. Elevated numbers of regulatory T cells, central memory T cells and classswitched B cells in cerebrospinal fluid of patients with anti-Hu antibody associated paraneoplastic neurological syndromes. J Neuroimmunol 2013; 258:85-90; http://dx.doi.org/10.1016/j.jneuroim.2013.02.006; PMID:23566401
59. Albert ML, Darnell JC, Bender A, Francisco LM, Bhardwaj N, Darnell RB. Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat Med 1998; 4:1321-4; http://dx.doi.org/10.1038/3315; PMID:9809559
60. Santomasso BD, Roberts WK, Thomas A, Williams T, Blachère NE, Dudley ME, Houghton AN, Posner JB, Darnell RB. A T-cell receptor associated with naturally occurring human tumor immunity. Proc Natl Acad Sci U S A 2007; 104:19073-8; PMID:18045792; http://dx.doi.org/10.1073/pnas.0704336104
61. Liblau RS, Gonzalez-Dunia D, Wiendl H, Zipp F. Neurons as targets for T cells in the nervous system. Trends Neurosci 2013; 36:315-24; http://dx.doi. org/10.1016/j.tins.2013.01.008; PMID:23478065
62. de Beukelaar JW, Verjans GM, van Norden Y, Milikan JC, Kraan J, Hooijkaas H, Sintnicolaas K, Gratama JW, Sillevis Smitt PA. No evidence for circulating HuD-specific CD8+ T cells in patients with paraneoplastic neurological syndromes and Hu antibodies. Cancer Immunol Immunother 2007; 56:1501-6; http://dx.doi.org/10.1007/s00262-007-0295-2; PMID:17597332
63. de Jongste AH, de Graaf MT, Martinuzzi E, van den Broek PD, Kraan J, Lamers CH, Mallone R, Gratama JW, Sillevis Smitt PA. Three sensitive assays do not provide evidence for circulating HuD-specific T cells in the blood of patients with paraneoplastic neurological syndromes with anti-Hu antibodies. Neuro Oncol 2012; 14:841-8; http://dx.doi.org/10.1093/ neuonc/nos118; PMID:22591661
64. Plonquet A, Garcia-Pons F, Fernandez E, Philippe C, Marquet J, Rouard H, Delfau-Larue MH, Kosmatopoulos K, Lemonnier F, Farcet JP, et al. Peptides derived from the onconeural HuD protein can elicit cytotoxic responses in HHD mouse and human. J Neuroimmunol 2003; 142:93-100; PMID:14512168; http://dx.doi.org/10.1016/ S0165-5728(03)00269-8
65. Rousseau A, Benyahia B, Dalmau J, Connan F, Guillet JG, Delattre JY, Choppin J. T cell response to Hu-D peptides in patients with anti-Hu syndrome. J Neurooncol 2005; 71:231-6; http://dx.doi. org/10.1007/s11060-004-1723-1; PMID:15735910
66. Tanaka M, Tanaka K. Pathogenesis and treatment of paraneoplastic neurologic syndrome. Expert Rev Neurother 2002; 2:901-9; http://dx.doi. org/10.1586/14737175.2.6.901; PMID:19810923
67. Roberts WK, Deluca IJ, Thomas A, Fak J, Williams T, Buckley N, Dousmanis AG, Posner JB, Darnell RB. Patients with lung cancer and paraneoplastic Hu syndrome harbor HuD-specific type 2 CD8+ T cells. J Clin Invest 2009; 119:2042-51; http://dx.doi. org/10.1172/JCI36131; PMID:19509467
68. Meresse B, Malamut G, Cerf-Bensussan N. Celiac disease: an immunological jigsaw. Immunity 2012; 36:907-19; http://dx.doi.org/10.1016/j. immuni.2012.06.006; PMID:22749351
69. DeLuca I, Blachère NE, Santomasso B, Darnell RB. Tolerance to the neuron-specific paraneoplastic HuD antigen. PLoS One 2009; 4:e5739; http://dx.doi.org/10.1371/journal.pone.0005739; PMID:19492067
70. Rosenblum MK. Paraneoplasia and autoimmunologic injury of the nervous system: the anti-Hu syndrome. Brain Pathol 1993; 3:199-212; PMID:8293180; ht tp: //dx.doi.org/10.1111/j.1750-3639.1993. tb00747.x
71. Galon J, Angell HK, Bedognetti D, Marincola FM. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 2013; 39:11-26; http:// d x.doi.org /10.1016 / j. immuni. 2013.07.008 ; PMID:23890060
72. Marrack P, Kappler JW. Do MHCII-presented neoantigens drive type 1 diabetes and other autoimmune diseases? Cold Spring Harb Perspect Med 2012; 2:a007765; http://dx.doi.org/10.1101/cshperspect. a007765; PMID:22951444
73. Sollid LM, Jabri B. Celiac disease and transglutaminase 2: a model for posttranslational modification of antigens and HLA association in the pathogenesis of autoimmune disorders. Curr Opin Immunol 2011; 23:732-8; http://dx.doi.org/10.1016/j. coi.2011.08.006; PMID:21917438
74. de Graaf MT, de Beukelaar JW, Haasnoot GW, Levering WH, Rogemond V, Didelot A, Honnorat J, Gratama JW, Smitt PA. HLA-DQ2+ individuals are susceptible to Hu-Ab associated paraneoplastic neurological syndromes. J Neuroimmunol 2010; 226:147-9; http://dx.doi.org/10.1016/j.jneuroim. 2010.05.035; PMID:20547426
75. Uchuya M, Fleury A, Graus F, Costagliola D, Liblau R, Merle-Beral H, Théodorou I, Delattre JY. Lack of association between human leukocyte antigens and the anti-Hu syndrome in patients with small-cell lung cancer. Neurology 1998; 50:565-6; PMID:9484403; http://dx.doi.org/10.1212/WNL.50.2.565
76. Pellkofer HL, Voltz R, Goebels N, Hohlfeld R, Dornmair K. Cross-reactive T-cell receptors in tumor and paraneoplastic target tissue. Arch Neurol 2009; 66:655-8; http://dx.doi.org/10.1001/archneurol. 2009.56; PMID:19433667
77. Bernal F, Graus F, Pifarré A, Saiz A, Benyahia B, Ribalta T. Immunohistochemical analysis of anti-Hu-associated paraneoplastic encephalomyelitis. Acta Neuropathol 2002; 103:509-15; http://dx.doi. org/10.1007/s00401-001-0498-0; PMID:11935268
78. Dalmau J, Posner JB. Neurologic paraneoplastic antibodies (anti-Yo; anti-Hu; anti-Ri): the case for a nomenclature based on antibody and antigen specificity. Neurology 1994; 44:2241-6; PMID:7991105; http://dx.doi.org/10.1212/WNL.44.12.2241
79. Bien CG, Vincent A, Barnett MH, Becker AJ, Blümcke I, Graus F, Jellinger KA, Reuss DE, Ribalta T, Schlegel J, et al. Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain 2012; 135:1622-38; http://dx.doi. org/10.1093/brain/aws082; PMID:22539258
80. Dalmau J, Furneaux HM, Rosenblum MK, Graus F, Posner JB. Detection of the anti-Hu antibody in specific regions of the nervous system and tumor from patients with paraneoplastic encephalomyelitis/ sensory neuronopathy. Neurology 1991; 41:1757-64; PMID:1944905; http://dx.doi.org/10.1212/ WNL.41.11.1757
81. Graus F, Campo E, Cruz-Sanchez F, Ribalta T, Palacin A. Expression of lymphocyte, macrophage and class I and II major histocompatibility complex antigens in normal human dorsal root ganglia. J Neurol Sci 1990; 98:203-11; PMID:1700807; http:// dx.doi.org/10.1016/0022-510X(90)90261-K
82. Antoine JC, Mosnier JF, Honnorat J, Convers P, Absi L, Lapras J, Michel D. Paraneoplastic demyelinating neuropathy, subacute sensory neuropathy, and anti-Hu antibodies: clinicopathological study of an autopsy case. Muscle Nerve 1998; 21:850-7; PMID:9626244; http://dx.doi.org/10.1002/ (SICI)1097-4598 (199807)21:7< 850: :AIDMUS2> 3.0.CO;2-5
83. Wanschitz J, Hainfellner JA, Kristoferitsch W, Drlicek M, Budka H. Ganglionitis in paraneoplastic subacute sensory neuronopathy: a morphologic study. Neurology 1997; 49:1156-9; PMID:9339709; http:// dx.doi.org/10.1212/WNL.49.4.1156
84. Plonquet A, Gherardi RK, Créange A, Antoine JC, Benyahia B, Grisold W, Drlicek M, Dreyfus P, Honnorat J, Khouatra C, et al. Oligoclonal T-cells in blood and target tissues of patients with anti-Hu syndrome. J Neuroimmunol 2002; 122:100-5; PMID:11777548; http://dx.doi.org/10.1016/ S0165-5728(01)00452-0
85. Kreutzfeldt M, Bergthaler A, Fernandez M, Brück W, Steinbach K, Vorm M, Coras R, Blümcke I, Bonilla WV, Fleige A, et al. Neuroprotective intervention by interferon-? blockade prevents CD8+ T cell-mediated dendrite and synapse loss. J Exp Med 2013; 210:2087-103; http://dx.doi.org/10.1084/ jem.20122143; PMID:23999498
86. Voltz R, Dalmau J, Posner JB, Rosenfeld MR. T-cell receptor analysis in anti-Hu associated paraneoplastic encephalomyelitis. Neurology 1998; 51:1146-50; PMID:9781545; http://dx.doi.org/10.1212/ WNL.51.4.1146
87. Siewert K, Malotka J, Kawakami N, Wekerle H, Hohlfeld R, Dornmair K. Unbiased identification of target antigens of CD8+ T cells with combinatorial libraries coding for short peptides. Nat Med 2012; 18:824-8; http://dx.doi.org/10.1038/nm.2720; PMID:22484809
88. Carpentier AF, Rosenfeld MR, Delattre JY, Whalen RG, Posner JB, Dalmau J. DNA vaccination with HuD inhibits growth of a neuroblastoma in mice. Clin Cancer Res 1998; 4:2819-24; PMID:9829748
89. Kazarian M, Calbo J, Proost N, Carpenter CL, Berns A, Laird-Offringa IA. Immune response in lung cancer mouse model mimics human anti-Hu reactivity. J Neuroimmunol 2009; 217:38-45; http://dx.doi.org/10.1016/j.jneuroim.2009.08.014; PMID:19765830
90. Pellkofer H, Schubart AS, Höftberger R, Schutze N, Pagany M, Schüller M, Lassmann H, Hohlfeld R, Voltz R, Linington C. Modelling paraneoplastic CNS disease: T-cells specific for the onconeuronal antigen PNMA1 mediate autoimmune encephalomyelitis in the rat. Brain 2004; 127:1822-30; http://dx.doi. org/10.1093/brain/awh205; PMID:15201193
91. Oh SJ, Dropcho EJ, Claussen GC. Anti-Hu-associated paraneoplastic sensory neuropathy responding to early aggressive immunotherapy: report of two cases and review of literature. Muscle Nerve 1997; 20:1576-82; PMID:9390671; http://dx.doi.org/10.1002/ (SICI) 1097-4598(199712)20 :12<1576: :AIDMUS13> 3.0.CO;2-Z
92. Brinkmann V, Billich A, Baumruker T, Heining P, Schmouder R, Francis G, Aradhye S, Burtin P. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 2010; 9:883-97; PMID:21031003; http:// dx.doi.org/10.1038/nrd3248
93. Ifergan I, Kebir H, Alvarez JI, Marceau G, Bernard M, Bourbonnière L, Poirier J, Duquette P, Talbot PJ, Arbour N, et al. Central nervous system recruitment of effector memory CD8+ T lymphocytes during neuroinflammation is dependent on a4 integrin. Brain 2011; 134:3560-77; http://dx.doi.org/10.1093/ brain/awr268; PMID:22058139
94. Planas R, Jelcic I, Schippling S, Martin R, Sospedra M. Natalizumab treatment perturbs memory-and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis. Eur J Immunol 2012; 42:790-8; http://dx.doi.org/10.1002/ eji.201142108; PMID:22144343
95. Scheikl T, Pignolet B, Dalard C, Desbois S, Raison D, Yamazaki M, Saoudi A, Bauer J, Lassmann H, Hardin-Pouzet H, et al. Cutting edge: neuronal recognition by CD8 T cells elicits central diabetes insipidus. J Immunol 2012; 188:4731-5; http://dx.doi. org/10.4049/jimmunol.1102998; PMID:22504649
96. Riley JL. Combination checkpoint blockade--taking melanoma immunotherapy to the next level. N Engl J Med 2013; 369:187-9; http://dx.doi.org/10.1056/ NEJMe1305484; PMID:23724866